Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7496353 Combination Therapy in Advanced Solid Tumors
NCT05867121Phase 1Completed
- Sponsor
- Genentech
- Start
- Oct 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of ro7496353 in non-small cell lung cancer (NSCLC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC) and 1 more (4 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events. Started Oct 2023; status: completed.
02
Drugs
ro7496353
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)pancreatic ductal adenocarcinoma (PDAC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05867121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867121.